News & Updates

Pain and quality of life (QoL) outcomes from the phase III PANOVA-3 trial reinforce the role of tumour treating fields (TTFields) therapy when added to a chemotherapeutic regimen consisting of gemcitabine/nab-paclitaxel (GnP) for the treatment of individuals with locally advanced pancreatic adenocarcinoma.

Participants with early-onset obesity in the SURMOUNT clinical trials show a mixed profile of metabolic health at baseline despite a relatively young biological age. They exhibit concerning features, such as higher waist circumference and fasting insulin, as well as favourable features, including lower systolic blood pressure (SBP) and HbA1c compared with the late-onset group.